Last reviewed · How we verify
bupropion + nicotine gum
Bupropion inhibits norepinephrine and dopamine reuptake to reduce cravings and withdrawal symptoms, while nicotine gum provides nicotine replacement therapy to satisfy addiction and support smoking cessation.
Bupropion inhibits norepinephrine and dopamine reuptake to reduce cravings and withdrawal symptoms, while nicotine gum provides nicotine replacement therapy to satisfy addiction and support smoking cessation. Used for Smoking cessation in adults with nicotine dependence.
At a glance
| Generic name | bupropion + nicotine gum |
|---|---|
| Sponsor | University of Wisconsin, Madison |
| Drug class | Combination smoking cessation therapy (antidepressant + nicotine replacement) |
| Target | Norepinephrine transporter, dopamine transporter (bupropion); nicotinic acetylcholine receptors (nicotine) |
| Modality | Small molecule |
| Therapeutic area | Addiction Medicine / Smoking Cessation |
| Phase | FDA-approved |
Mechanism of action
Bupropion is an atypical antidepressant that increases dopamine and norepinephrine availability in the brain, reducing the reward deficit and withdrawal symptoms associated with nicotine cessation. Nicotine gum delivers nicotine transdermally through oral mucosa, satisfying nicotine dependence while allowing gradual dose reduction. The combination addresses both the neurochemical and behavioral components of tobacco addiction.
Approved indications
- Smoking cessation in adults with nicotine dependence
Common side effects
- Insomnia
- Dry mouth
- Nausea
- Headache
- Dizziness
- Jaw soreness (from gum)
- Hiccups
- Seizures (bupropion)
Key clinical trials
- Tobacco Treatment Optimization and Preferences During Concurrent Cancer Treatment (PHASE2)
- A Smart Approach to Treating Tobacco Use Disorder in Persons Living With HIV (PHASE4)
- Nicotine Replacement Therapy, Counseling, Varenicline, and Bupropion for Smoking Cessation, the PISCES I Trial (PHASE4)
- Effectiveness of an Enhanced Tobacco Intervention Protocol Compared to Standard Treatment in Helping Head and Neck and Lung Cancer Patients Starting Treatment to Reduce Cigarette Use (NA)
- Effectiveness of a Smoking Cessation Algorithm Integrated Into HIV Primary Care (PHASE4)
- Preference-based Tools for Smoking Cessation Among Disadvantaged Smokers, a Pragmatic Randomised Controlled Trial (NA)
- Embedding Comprehensive Smoking Cessation Programs Into Community Clinics (NA)
- Mobile Evidence-Based Smoking Cessation for Veterans Living With HIV (MESH) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- bupropion + nicotine gum CI brief — competitive landscape report
- bupropion + nicotine gum updates RSS · CI watch RSS
- University of Wisconsin, Madison portfolio CI